Barostim

CVRx is a commercial-stage medical device company headquartered in Minneapolis, Minnesota, specializing in neuromodulation therapies for cardiovascular diseases. The company's primary product, the Barostim System, is an implantable device designed to treat patients with heart failure with reduced ejection fraction (HFrEF) and resistant hypertension. Barostim works by electrically stimulating baroreceptors in the carotid sinus, which triggers the body's natural blood pressure regulation system to balance the autonomic nervous system. This mechanism, known as Baroreflex Activation Therapy (BAT), reduces sympathetic activity and enhances parasympathetic activity. CVRx received FDA Premarket Approval (PMA) for Barostim in 2019, making it the first device of its kind in the heart failure market. The company is actively expanding its commercial footprint and conducting further clinical trials to broaden the indications for its neuromodulation platform.